targeted therapy

(redirected from Targeted cancer therapy)

targeted therapy

A generic term for therapies that impact on a specific molecular pathway, target or ligand.

Examples
Gefitimib for non-small cell carcinoma of the lungs with mutations in epidermal growth factor receptor, and imatinib for GIST tumours with activating mutations in c-Kit.
References in periodicals archive ?
As the industry leader in ADCs, we bring deep expertise in targeted cancer therapy development to this collaboration with Pieris," said Dennis Benjamin, Ph.
This expensive antibody is used for targeted cancer therapy, and has been reduced by over INR10,000.
6 against truncated O-glycan on MUC16, for targeted cancer therapy applications.
NEW YORK -- Because of the frequency with which patients develop pruritus while on a targeted cancer therapy, prophylaxis should be strongly considered for at least some of the drugs, such as epidermal growth factor-receptor (EGFR) inhibitors, according to an expert in oncodermatology.
Handbook of Targeted Cancer Therapy (online access included)
Gefitinib is a targeted cancer therapy that blocks a tyrosine kinase enzyme to treat non-small cell lung cancers caused by mutations in the epidermal growth factor receptor.
Jude Children's Research Hospital, Memphis) bring together a group of North American and European specialists in TOR signaling to discuss targeted cancer therapy in the areas of mTOR (mammalian target of rapamycin) signaling and therapeutic targeting downstream of mTOR.
In the framework of a strategic alliance of DKFZ with Bayer-Schering, the researchers in Kramer's team are now planning to look among the identified genes for suitable targets for a targeted cancer therapy.
On February 19, 2002, the FDA approved ZEVALIN, a new type of targeted cancer therapy called radioimmunotherapy, making it the first commercially available radioimmunotherapy for the treatment of B-cell non-Hodgkin's lymphoma (NHL).
AstraZeneca's TAGRISSO is an EGFR-tyrosine kinase inhibitor (TKI), a targeted cancer therapy, designed to inhibit both the activating, sensitizing mutations (EGFRm), and T790M, the genetic mutation responsible for EGFR-TKI treatment resistance in up to approximately two-thirds of cases of EGFRm advanced NSCLC.
Successes and Limitations of Targeted Cancer Therapy
This work provides a review of the state of the art of targeted cancer therapy, covering new and emerging technologies in target identification, drug discovery, molecular markers, and imaging.

Full browser ?